Infant Bacterial Therapeutics
Presence
BioGaia is a company listed under the stock ticker BIOGB (SE).
They are in:
- Biotechnology50%
- Pharmaceuticals50%
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Infant Bacterial Therapeutics
Create your alert
to follow the executive moves at Infant Bacterial Therapeutics.
Pharmaceuticals
BioGaia has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Infant Bacterial Therapeutics
- IBT | Notice of Annual General Meeting of Infant Bacterial Therapeutics
- IBT | Major Milestone Achieved – Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study
- IBT | Infant Bacterial Therapeutics AB publishes the Annual Report for 2023
- IBT | Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
- IBT | Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023
- IBT | Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024
- IBT | Press Releases
- IBT | News
- IBT | Press Releases
- View more press releases Close
Social media about Infant Bacterial Therapeutics
- Infant Bacterial Therapeutics on Wikipedia, Google News & Yahoo Finance
- Infant Bacterial Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Staffan Stromberg 
Call Infant Bacterial Therapeutics at +46 84...
